TAK 083

Drug Profile

TAK 083

Alternative Names: TAK-083

Latest Information Update: 16 Feb 2006

Price : $50

At a glance

  • Originator Takeda
  • Class Antibacterials; Indoles
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Helicobacter infections

Most Recent Events

  • 16 Feb 2006 No development reported - Preclinical for Helicobacter infections in Japan (unspecified route)
  • 23 Oct 2001 A preclinical study has been added to the Bacterial Infections antimicrobial activity and pharmacodynamics sections
  • 14 Sep 2001 Preclinical development for Helicobacter infections in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top